Q-omics provides the consensus-scored PKHD1 profile across patient tissues and cancer cell-line models. PKHD1 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, PKHD1 is differentially expressed in 10, with the highest sampling consensus in KICH. Additionally, PKHD1 RNA expression shows 15,702 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, KICH, and KIRP as cancer lineages where PKHD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PKHD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PKHD1 survival associations across molecular data types. PKHD1 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PKHD1 RNA expression–survival associations across cancer types. High PKHD1 expression shows unfavorable associations in COAD and THYM, but favorable associations in KIRC, SCLC, UCS and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for PKHD1 RNA expression.
This table summarizes PKHD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for PKHD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PKHD1 shows lower tumor expression in KICH, KIRC, THCA and BRCA and higher tumor expression in HNSC and STAD. The KICH box plot shows higher PKHD1 RNA expression in normal versus tumor tissue (log2 FC = −4.733, t-test p < 0.001).
This table shows molecular features associated with PKHD1 in patient tissues and cancer cell lines. In patient samples, PKHD1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, PKHD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
